عملکرد استراتژی تجاری سازی مشارکتی: ائتلاف استراتژیک

نوع مقاله : مقاله پژوهشی

نویسندگان

1 استادیار گروه مدیریت، دانشکده علوم انسانی، دانشگاه آزاد اسلامی، سنندج، ایران

2 استاد گروه مدیریت، دانشگاه سیستان و بلوچستان، ایران

10.29252/bar.2022.13172.3347

چکیده

یک انتخاب استراتژیک بسیار مهم شرکت­های فناوری­محور در صنعت داروهای زیستی، استراتژی تجاری­سازی است. تشکیل ائتلاف­های استراتژیک یکی از شیوه­های غالب تجاری‌سازی در صنعت زیست­داروها است. هدف پژوهش حاضر، طراحی مدل جامع عوامل تعیین­کننده عملکرد استراتژی تجاری­سازی مشارکتی در صنعت داروهای زیستی کشور با رویکرد پنج مرحله­ای مک­کنزی شامل؛ طراحی تحقیق، انجام تحقیق و ساخت مدل، اعتبارسنجی تحقیق، تجزیه­وتحلیل داده‌ها و گزارش تحقیق است. به ­منظور ساخت مدل مفهومی پژوهش، بر اساس مرور نظام­مند ادبیات پژوهش، سازه­های تعیین­کننده شناسایی شدند. نتیجه اعتبارسنجی مدل مستخرج از ادبیات­ بر اساس نظر خبرگان صنعت داروئی کشور با روش رتبه اعتبار محتوایی لاوشه از این قرار است: عوامل؛ تناسب شرکاء، سرمایه رابطه­ای، مدیریت تعارض، قابلیت پویای مدیریت ائتلاف و اعتماد به‌عنوان پیش­بین­های عملکرد استراتژی تجاری­سازی مشارکتی مطرح هستند. لازم به ذکر است که عوامل استخراجی دیگر نظیر؛ پویائی محیطی، رفتار فرصت­طلبانه، اداره ائتلاف، ترکیب منابع مولد، رژیم­های مالکیت، یادگیری و سرمایه اجتماعی در صنعت بایوسیمیلارهای کشور مطمح نظر نبوده است.

کلیدواژه‌ها


عنوان مقاله [English]

Performance of the collaborative commercialization strategy: Strategic alliance

نویسندگان [English]

  • Roya Shakeri 1
  • Noormohammad Yaghoubi 2
1 Assistant Professor, Department of Management, Faculty of Humanities, Islamic Azad University, Sanandaj, Iran
2 Professor, Department of Management, University of Sistan and Balouchestan, Iran
چکیده [English]

Introduction: The biopharmaceutical industry has several notable characteristics such as high R&D costs of $ 125 million to $ 250 million per drug, long-term commercialization cycles, and very complex and often long-term legislative procedures. All of these are associated with a high level of inherent uncertainty in the innovation process. Another characteristic of the biotechnology industry is the division of the innovative workforce between biotechnology R&D firms and pharmaceutical firms (customers) according to their capabilities. Dynamic knowledge bases such as genomes, molecular biology and proteomics as well as the novelty and fluidity of the biotechnology industry's scientific and technical knowledge needed to develop new products. This shows that the collaboration between companies is beneficial. Because the biotechnology industry includes a population of relatively young companies (e.g., proprietary biotechnology companies), there exists research partnership among these venture entrepreneurs, established and sustainable companies, and / or universities (Sorrentino and Garaffo, 2012) As mentioned above, adopting a strategy of participatory commercialization in today's changing environment is one of the vital business strategies of the firm (Standing et al., 2008). The increasing trend of coalition building since the 1980s and the increasing share of revenue from the implementation of this strategy in firms indicate the growing importance of their use (Kanzanilo et al., 2017). The output of the participatory approach has received much attention as a commercialization strategy in the form of performance, and many researchers have looked at the issue from different dimensions and angles. However, the lack of a comprehensive view of all the dimensions and constructs that determine performance is felt in the research literature. Thus, the present study seeks to identify the determinants of the performance of the participatory commercialization strategy (strategic alliance) in the bio-pharmaceutical industry (biosimilar). The study helps to develop the theoretical foundations of commercialization strategies by reviewing the latest articles in the reputable scientific databases. Then, a model extracted from the research literature is validated through the group modeling technique by 20 industry experts and 10 academic experts. The results are presented as the final model in the research.
Methodology: In general, the design of the present study is based on the five-step approach presented by McKenzie et al. (1999). Accordingly, the research stages include 1) research design: explaining the problem and reviewing the theoretical background, 2) conducting research and model construction: developing a conceptual framework and determining the relevant structures, 3) research validation: general validation of research and data collection, 4) data analysis: analysis of the results using descriptive-analytical statistical methods and partial least squares, and 5) reporting the research results: summarizing the research findings and documenting the research analyses. The present study is in the field of combined research (qualitative-quantitative) in terms of the purpose and developmental in terms of data nature and analysis style. This research in the qualitative part is done through interviews and in the quantitative part through surveys. According to the objectives and type of the research, in terms of the methodology, survey is the most appropriate method. It is a method in which measurement tools are used to obtain data about the statistical sample with high accuracy, speed and efficiency, and its results can be generalized to a larger community. The sampling method in this research in the qualitative part is theoretical sampling, and the statistical population of the research is all the research published in valid domestic and foreign scientific databases until 2020. The studies have been scoured in order to obtain a sample that causes theoretical saturation. Theoretical validity was the basis of the validity of this study. In order to achieve it, extensive field studies, theoretical pluralism, and experts’ opinions were used. In addition, the model for performance prediction by the Biopharma's participatory commercialization strategy in Iran has been done through the validation steps of Lavache (1975).
Results and Discussion: In this study, a group of 30 people was selected as the focus group. Based on the criterion of action and the structure of the conceptual model, the value of content validity ratio (CVR) was calculated. The demographic characteristics of respondents included age, level of education, gender, history of activity in the field of medicine, history of activity in the field of biosimilars, and research background in the field of biosimilars commercialization strategies. Most experts (more than 70%) were in the age range of 36 to 51 years. More than 83% of the responding experts had PhD degrees. Only one female respondent was present in the panel of experts. More than 75% of the experts had at least six years of experience in the pharmaceutical field. More than 46% of them had more than 10 years of experience in the field of biosimilars. In addition to the history of practical activities in the field of biopharma, the panel of research experts had research backgrounds. There were also master's theses, doctoral dissertations, books, dissertation consultations, articles, and research projects. The quorum required for the content validity ratio for each of the indicators waa 0.33.
Conclusion: This study addresses a set of underlying factors including dynamic management of coalition capability, social capital, learning, ownership regimes, productive resource composition, coalition governance, opportunistic behavior, trust, conflict management, relational capital, partner appropriateness and environmental dynamics. The study aims at the formation of strategic alliances for the commercialization of biopharmaceuticals. In previous studies, however, these factors were not examined simultaneously and comprehensively. Currently, the dominant commercialization in the Iranian biosimilar industry is based on an independent and individualized strategy.

کلیدواژه‌ها [English]

  • Collaborative Commercialization Strategy
  • Strategic alliance
  • Mackenzie Approach
  • bio-pharmaceutical
Agha jani, T., Reza zadeh, A., Shoghi, B. (2015). The Effect of Strategic Alliance on Organizational Performance case: Alliance between Arak Aluminum Rolling and Aluminum Pars, Strategic Management Research, Twentieth Year, 55, 9-34.
Ahn, M. J., Meeks, M., Davenport, S., Bednarek, R. (2010). Exploring technology agglomeration patterns for multinational pharmaceutical and biotechnology firms, Journal of Commercial Biotechnology, 16(1), 17–32.
Al-Laham, A., L. Amburgey, T., Batesw, K. (2007). The Dynamics of Research Alliances: Examining the Effect of Alliance Experience and Partner Characteristics on the Speed of Alliance Entry in the Biotech Industry, British Journal of Management, 19 (343–364).
António, F., & Mário, F. (2017). he Mediating Effect of Intellectual Capital in The Relationship Between Strategic Alliances and Organizational Performance in Portuguese Technology-Based SMEs. European Management Review, 14(3), 303-318.
Bagchi-Sen, S. (2007). Strategic Considerations for Innovation and Commercialization in the US Biotechnology Sector, European Planning Studies, 15(6), 753-766.
Cacciolattia, L., Roslib, A., Ruiz-Albaa, J.L., Changc, J. (2020). Strategic alliances and firm performance in startups with a social mission, Journal of Business Research,106, 106–117.
Caerteling, J.S., Halman, J.I.M., Dore´e, A.D. (2008). Technology Commercialization in Road Infrastructure: How Government Affects the Variation and Appropriability of Technology, J Prod Innov Manag, 25, 143–161.
Chia-Nan Wang, Xuan-Tho Nguyen∗, Thi-Dao Le, Ming-Hsien Hsueh. (2018). A partner selection approach for strategic alliance in the global aerospace and defense industry, Journal of Air Transport Management, 69, 190–204.
Christoffersen, J. (2013). A Review of Antecedents of International Strategic Alliance Performance: Synthesized Evidence and New Directions for Core Constructs, International Journal of Management Reviews, 15, 66–85.
Das, T.K., Teng, B.S. (2001). Relational Risk And Its Personal Correlates In Strategic Alliances, Journal Of Business And Psychology, 15(3), 449-465.
Deeds, D.L., Rothaermel, F.T. (2003). Honeymoons and Liabilities: The Relationship between Age and Performance in Research and Development Alliances, Product Development & Management Association, 20, 468 – 484.
Diestre, L., Pajagopalan, N. (2012). Are All ‘Sharks’ Dangerous? New Biotechnology Ventures And Partner Selection In R&D Alliances, Strategic Management Journal, 33, 1115–1134. 
Dostar, M., Shakiba Jamalabad, Gh. (2019). Explaining the Sustainability Pattern of Strategic Alliance by Exploratory Hybrid Method, Strategic Management Research, Twenty-fifth Year, 73, 113-132.
Gans, J. S., Stern, S. (2003). The product market and the market for “ideas”: commercialization strategies for technology entrepreneurs, Research Policy, 32,  333-350.
Gonçalves, F. R, Gonçalves, V. D. C (2008). Strategic alliances and competitive performance in the pharmaceutical industry, Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, 8(1), 69-76. 
Goncalves, F.R., Goncalves, V.D.C. (2011). The role of the alliance management capability, The Service Industries Journal, 31(12), 1961 –1978.
Gopalakrishnan, S., Scillitoe, J.L., Santoro, M.D. (2008). Tapping Deep Pockets: The Role of Resources and Social Capital on Financial Capital Acquisition by Biotechnology Firms in Biotech–Pharma Alliances, Journal of Management Studies, 45(8), 1354-1376.
Gulati, R., Lavie, D., Singh, H. (2009). The Nature Of Partnering Experience And The Gains From Alliances, Strategic Management Journal, 30, 1213–1233.
Haghighi Shoemaker, M., Sadeghi, D., Qasemi, A. (2013). Ranking Factors Influencing the Success of Airlines Strategic Alliance From the Experts' Viewpoint, Journal of Tourism Management Studies, Eighth Year, 23, 27-50.
Harrigan, K. R. (1988). Strategic alliances and partner asymmetries, Management International Review, 28, 53–72.
He, W., Kundu, S., Zhao, J. (2013). Alliances? Partners? Or Both? The Effects Of Alliance Portfolio Heterogeneity On Multinational Firms’ Performance, International Journal of Business Strategy, 13(4), 171-186.
Heimeriks, K.H., Duysters, G. (2007). Alliance Capability as a Mediator Between Experience and Alliance Performance: An Empirical Investigation into the Alliance Capability Development Process, Journal of Management Studies 44(1), 25-49.
Hess, A. M., Rothaermel, F. T (2011). When Are Assets Complementary? Star Scientists, Strategic Alliances, And Innovation In The Pharmaceutical Industry, Strategic Management Journal, 32, 895-909.  
Hoang, H., and Rothaermel, F.T. (2005).The Effect Of General And Partner-Specific Alliance Experience On Joint R&D Project Performance, Academy of Management Journal, 48(2), 332–345.
Hoetker, G., Mellewigt, T. (2009). Choice And Performance Of Governance Mechanisms: Matching Alliance Governance To Asset Type, Strategic Management Journal, 30, 1025–1044.
Hosseinian Pouya, H., Ghaznouri, S., Goodarzi, M. (2015). Identifying Factors Affecting Technology Commercialization Strategy Using the Hybrid Method, Journal of Technology Development Management, 3(1), 63-97.
Hurmelinna-Laukkanen, P., Puumalainen, K. (2007). Nature and dynamics of appropriability: strategies for appropriating returns on innovation, R&D Management, 37(2), 95-112.
INSEAD, H.H., ROTHAERMEL, F.T. (2005). The Effect Of General And Partner-Specific Alliance Experience On Joint R&D Project Performance, Academy of Management Journal, 48(2), 332-345.
Jafarnejad, A., Elft, L., Mokhtarzadeh, N., Eliassi, M., Forgery, SA. (2018). Value Acquisition in Technological Strategic Alliances and Factors Affecting Its Different Dimensions, Journal of Technology Development Management, 6(1), 9-48.
Jalali, SA (2012). Explaining the Content Components of Partner Selection in Strategic Alliances: A Study in the Software Industry, Iranian Journal of Management Science, Seventh Year, 27, 147-168.
 Jiang, X., Jiang, F., Cai, X., & Liu, H. (2015). How does trust affect alliance performance? The mediating role of resource sharing. Industrial Marketing Management, 45, 128–138.
Judge, W.Q., Dooley, R. (2006). Strategic Alliance Outcomes: a Transaction-Cost Economics Perspective, British Journal of Management, 17, 23–37.
Kale, P., & Singh, H. (2007). Building firm capabilities through learning: The role of the alliance learning process in alliance capability and firm-level alliance success, Strategic Management Journal, 28, 981-1000.
Kale, P., and Singh, H. (2009). Managing Strategic Alliances: What Do We Know Now, and Where Do We Go From Here?, Academy of management perspectives, 45-62.
Kale, P., Singh, H., Perlmutter, H. (2000). Learning and protection of proprietary assets in strategic alliances: building relational capital, Strategic Management Journal, 21(3), 217–237.
Kapmeier, F. (2008). Common Learning and Opportunistic Behaviour in Learning Alliances, Systems Research and Behavioral Science, 25, 549-573.
Karamanos, A.G. (2012). Leveraging micro- and macro-structures of embeddedness in alliance networks for exploratory innovation in biotechnology, R&D Management, 42(1), 71-89.
Kebriaeezadeh, A., Nassiri Koopaei, N., Abdollahiasl, A., Nikfar, SH., Mohamadi, N. (2010). Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing Countries.
Kim, J. (2011). Alliance governance and technological performance: some evidence from biotechnology alliances, Industrial and Corporate Change, 20 (4), 969–990.
Lane, P.J., Salk, J.A., Lyles, M.A. (2001). Absorptive Capacity, Learning, And Performance In International Joint Ventures, Strategic Management Journal, 22, 1139–1161.
Lavie, D., Haunschild, P.R., Khanna, P. (2012). Organizational Differences, Relational Mechanisms, And Alliance Performance, Strategic Management Journal, 33, 1453–1479.
Lawshe, C.H. (1975). A quantitative approach to content validity, Personnel Psychology, 28, 563-575.
Li, D., Eden, L., A.Hitt, M., Ireland, R.D. (2008). Friends, Acquaintances, Or Strangers? Partner Selection In R&D AllianceS, Academy of Management Journal, 51(2), 315–334.
Lin, Z., Yang, H., and Arya, B. (2009). Alliance Partners And Firm Performance: Resource Complementarity And Status Association, Strategic Management Journal, 30, 921–940.
Lonial, S. C., & Carter, R. E. (2015). The impact of organizational orientations on medium and small firm performance: A resource-based perspective. Journal of Small Business Management, 53(1), 94–113.
Makizadeh, V., Abolhosseini, N. (2017). Conceptual Model of Strategic Alliance Performance by Structural Equation Modeling Approach (Case Study: Oil Industry), Business Reviews, 90-91, 93-107.
Mazloomi Khamseh, H., Jolly, D., & Morel, L. (2017). The effect of learning approaches on the utilization of external knowledge in strategic alliances. Industrial Marketing Management, 63, 92–104.
Mowery, D. C., J. E. Oxley and B. S. Silverman (1996). Strategic alliances and interfirm knowledge transfer, Strategic Management Journal, Winter Special Issue, 17, 77–92.
Mu, J., Di Benedetto, C. A. (2011). Strategic orientations and new product commercialization:  mediator, moderator, and Interplay, R&D Management, 41(4), 337-359.
Naqshbandi, M.M., and Kaur, S. (2011). Relative Capacity Dimensions and Open Innovation, Journal of Management Research, 11(2), 77-86.
Nielsen, B.B., Nielsen, S. (2009). Learning and Innovation in International Strategic Alliances: An Empirical Test of the Role of Trust and Tacitness, Journal of Management Studies, 46(6), 1031-1056.
Pangarkar, N., Wu, J. (2013). Alliance formation, partner diversity, and performance of Singapore startups, Asia Pac J Manag, 3, 791–807.
Radfer, R., Pille wari, N., Ghazi noury, S.S, Shakeri, R. (2015). Studying Strategic Alliance Capability Properties at the Firm; The Case of the Biomedical Industry, Public Management Research, Eighth Year, 27, 70-45.
Sambasivan, M., Siew-Phaik, L., Abidin-Mohamed, Z., Choy-Leong, Y., (2011). Impact of interdependence between supply chain partners on strategic alliance outcomes: role of relational capital as a mediating construct. Management Decision, 49(4), 548–569.
Shi, W., and Prescott, J.E. (2011). Sequence Patterns of Firms’ Acquisition and Alliance Behaviour and their Performance Implications, Journal of Management Studies, 48(5), 1044- 1070.
Shi, W., Sun, J., Prescott, J.E. (2012). A Temporal Perspective of Merger and Acquisition and Strategic Alliance Initiatives: Review and Future Direction, Journal of Management, 38(1), 164-209.
Sorrentino, F., Garraffo, F. (2012). Explaining performing R&D through alliances: Implications for the business model of Italian dedicated biotech firms, J Manag Gov, 16, 449–475.
Standing, S., Standing, C., Lin, C. (2008). A Framework for Managing Knowledge in Strategic Alliances in the Biotechnology Sector, Systems Research and Behavioral Science, 25, 783-796.
Thornhill, S., Amit, R., (2003). Learning about failure: Bankruptcy, firm age, and the resource-based view, Organization Science, 14, 497-509.
Va´zquez, E.D.M., Angel Jime´nez Martı´n, j., and Mascaren˜as, J. (2006). Strategic alliances as a mechanism for wealth creation in the biopharmaceutical industry: An empirical analysis of the Spanish case, Journal Of Commercial Biotechnology, 12(3), 229–236. 
Welter, C., Bosse, D. A., Alvarez, S.A. (2013). The Interaction between Managerial and Technological Capabilities as a Determinant of Company Performance: An Empirical Study of Biotech Firms, International Journal of Management, 30(1), 272-284.
West, P.G., Noel, T.W. (2009). The impact of knowledge resources on new venture performance, Journal of Small Business Management, 47, 1-22.
Wiklund, J., Shepherd, D.A. (2009). The Effectiveness of Alliances and Acquisitions: The Role of Resource Combination Activities, Entrepreneurship Theory and Practice, 193-212.
Xiong, G., Bharadwaj, S. (2011). Social Capital of Young Technology Firms and Their IPO Values: The Complementary Role of Relevant Absorptive Capacity, Journal of Marketing, 75, 87–104.